Low-density lipoprotein lowering and atherosclerosis progression: Does more mean less?

Circulation

Volumn 106, Issue 16, 2002, Pages 2039-2040

  Shah, Prediman K ^a  

^a Department of Medicine   (United States)

Author keywords

Atherosclerosis; Editorials; Lipoproteins; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERLIPIDEMIA; PLEIOTROPY; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; CAROTID ARTERIES; CHOLESTEROL; CHOLESTEROL, LDL; DISEASE PROGRESSION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; PRAVASTATIN; PYRROLES;

EID: 0037109085     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000037742.25731.3D     Document Type: Editorial

References (18)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Coronary Prevention Study Group: prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
4. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615-1622.
6. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 6 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;2053;360:7-22.
7. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA. 1998;279:1643-1650.
8. McFarlane SI, Muniyappa R, Francisco R, et al. Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab. 2002;87:1451-1458.
9. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106:2055-2060.
10. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153-162.
11. White CW, Gobel FL, Campeau L, et al. Effect of aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial. Circulation. 2001;104:2660-2665.
12. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective randomized double blind trial. Lancet. 2001;357:577-581.
13. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation. 1998;97:1446-1452.
14. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998;97:1440-1445.
15. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-Co A reductase inhibitors: similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
16. Forrester J, Bairey-Merz N, Kaul S. The aggressive low density lipoprotein controversy. J Am Coll Cardiol. 2000;36:1419-1425.
17. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming: part I. Circulation. 2001;104:2376-2383.
18. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming: part II. Circulation. 2001;104:2498-2502.